1. Pharmacokinetics and Bioavailability Comparison of Generic and Branded Citalopram 20 mg Tablets

   • Tao Jiang
   • Zhengxing Rong
   • Hongzhuan Chen

   Original Research Article 22 November 2012 Pages: 1 - 9

   

2. Effect of Renal or Hepatic Impairment on the Pharmacokinetics of Mirabegron

   • James Dickinson
   • Michaelene Lewand
   • Marcel van Gelderen

   Original Research Article 04 December 2012 Pages: 11 - 23

   

3. Bioequivalence and Tolerability Assessment of a Novel Intravenous Ciclosporin Lipid Emulsion Compared to Branded Ciclosporin in Cremophor^® EL

   • Karl Henrik Johannes Ehinger
   • Magnus Joakim Hansson
   • Eskil Elmér

   Original Research Article Open access 22 November 2012 Pages: 25 - 34

   

4. Real-World Treatment of Post-herpetic Neuralgia with Gabapentin or Pregabalin

   • Phaedra Johnson
   • Laura Becker
   • Michael Sweeney

   Original Research Article Open access 23 November 2012 Pages: 35 - 44

   

5. Cardiovascular Safety of Anagrelide in Healthy Subjects: Effects of Caffeine and Food Intake on Pharmacokinetics and Adverse Reactions

   • Manuel Martínez-Sellés
   • Tomás Datino
   • Francisco Fernández-Avilés

   Original Research Article Open access 27 November 2012 Pages: 45 - 54

   

6. Efficacy and Safety of Cytoreductive Therapies in Patients with Essential Thrombocythaemia Aged >80 Years: An Interim Analysis of the EXELS Study

   • Jean-Jacques Kiladjian
   • Carlos Besses
   • Gunnar Birgegård

   Original Research Article Open access 27 November 2012 Pages: 55 - 63

   

7. Pulmonary Hypertension: Use of Oral Drugs in Patients with Renal Insufficiency

   • Sarah Zimner-Rapuch
   • Sabine Amet
   • Vincent Launay-Vacher

   Commentary 11 December 2012 Pages: 65 - 69

8. Propiverine

   • Kate McKeage

   Adis Drug Evaluation 04 January 2013 Pages: 71 - 91

   

9. Fidaxomicin in the Treatment of Clostridium difficile-Associated Diarrhoea

   • James Greig

   Correspondence 12 December 2012 Pages: 93 - 94

10. Erratum to: Efficacy and Safety of Olmesartan Medoxomil 40 mg/Hydrochlorothiazide 12.5 mg Combination Therapy versus Olmesartan Medoxomil 40 mg Monotherapy in Patients with Moderate to Severe Hypertension

    • Roberto Fogari
    • Stefano Taddei
    • Kai Schumacher

    Erratum 20 December 2012 Pages: 95 - 95